Summary We have carried out experiments to determine the response of tumours and normal tissues in the C3H mouse to the combination of lipophilic nitroimidazoles and CCNU, cyclophosphamide or melphalan. The nitroimidazoles studied were Ro 07-1902Ro 07- (1902 
It has been shown that by adding the radiosensitizer, misonidazole (MISO), to the nitrosourea, CCNU, an increase in the response of experimental mouse tumours can be achieved without a concommitant increase in normal tissue toxicity (Siemann, 1981 (Siemann, , 1982 Twentyman, 1981; Hirst et al., 1982) . Following these observations, we examined the ability to enhance the effect of CCNU against the KHT sarcoma of a series of neutral 2-nitroimidazoles, similar in electron-affinity but varying in octanol-water partition coefficient (PC) over 4 orders of magnitude . Analogues more hydrophilic than MISO were inactive, as were those with very high PCs (i.e. >20, MISO=0.43) . Those with PCs between 0.43 and 20 were usually more active than MISO, and two of the most effective agents were benznidazole (Ro 07-1051, BENZO) and Ro 07-1902 (1902) . Dose-response curves for these agents showed that benznidazole was effective down to very low doses (0.05-0.3 mmol kg-1).
In this paper we examine in more detail the effects of BENZO and 1902 in combination with CCNU on the response of the KHT tumour and of normal tissues in the mouse. We also report upon experiments combining these agents with cyclophosphamide (CTX) and mephalan (MEL) in the RIF-I mouse sarcoma.
Materials and methods

Mice and tumours
The mice used in these studies were inbred C3H/He supplied by OLAC. Females were used in most experiments but males were used occasionally. Mice entered experiments at age 12-16 weeks and weighed 20-28 g. Tumours used were the KHT and RIF-I sarcomas, both of which originated in C3H/Km mice at Stanford University, California, and which have been previously described (Kallman et al., 1967; Twentyman et al., 1980) . The methods used for tumour cell inoculation into the gastrocnemius muscle of the hind limb and subsequent measurement of tumour growth, including conversion of leg measurement to tumour weight, have also been described (Twentyman et al., 1979) . The endpoint of growth delay was calculated from the time taken for each tumour to reach 4 times its initial treatment volume. Tumours were treated in the size range 300-600mm3.
Nine to 12 mice were used in each treatment group.
White-cell counts Blood samples were taken from non-anaesthetised (Workman et al., 1978) except that the mobile phase was 60% methanol/water.
Results
Tumour response to CCNU
We have previously shown that, in terms of enhancement of CCNU effect against the KHT tumour, 1902 is the most effective sensitizer at a dose of 2.5mmolkg-1, but that BENZO is better able to retain its effectiveness at low doses (Workman et al., in preparation) , and we therefore investigated whether a longer interval would produce greater enhancement of CCNU. The results of an experiment using different timing intervals between BENZO (0.3 and 2.5mmolkg-1) and CCNU (10mgkg-1) are shown in Figure 2 . At 0.3 mmol kg-1 BENZO, the enhancement appears to be similar for sensitizer adminstration between 8h before and 1 h after CCNU. The effect is lost, however, if BENZO is not given until 4 h after CCNU. At the higher dose of BENZO, similar enhancement is seen for administration 8 h or 30 min before CCNU. These conclusions were confirmed in a repeat experiment in which we were also able to show significant enhancement of CCNU (0mg kg-1) by 0.3 mmol kg-1 BENZO given 28 or 18 h previously. The growth delays (± 2 s.e.) were CCNU (l0mgkg-1) alone=3. Figure  3 , that the sensitization to CCNU produced by BENZO is independent of the relative time of administration. The growth delay produced by 12 mg kg 1 CCNU in mice receiving multiple BENZO was similar to that produced by 18mg kg1 CCNU in mice receiving vehicle. Figure 5 . In each experiment, 1902 alone depressed the day 3 white cell count, and the data are therefore shown in two ways. In Figure 5a the absolute values are shown, whereas in Figure 5b the counts have been normalised to 100% in order to remove the initial effect of the sensitizer alone. It may be seen from Figure 5b that the response curve to CCNU is steepened in the presence of 1902 and that the % counts are significantly lower at 20 and 30mgkg-1 of CCNU. At 40mg kg-1, however, the curves tend to come together. From the CCNU doses required to reduce the initial counts to 50% on the basis of the normalised data, a DMF for 1902 of 1.6 is obtained.
Three WBC experiments were carried out in which 0.3 mmol kg-1 of BENZO was added to CCNU. The results have been combined and are shown in Figure 6 . There is again a tendency (not significant) for BENZO alone to reduce the count. At 10mgkg-1 of CCNU there is a significant effect of the sensitizer but no significant difference is seen at the higher doses. From the CCNU doses required to reduce the initial normalised counts to 50%, a DMF for BENZO of 1.2 is obtained. The available data from our own work and from other workers (Siemann, 1981 (Siemann, , 1982 Hirst et al., 1982) are not sufficiently precise to enable us to 4.4(2.8-6.2) 2.9(1.8-4.2) 7.5 5.6(4.4-6.9) 4.0(2.5-5.7) 5.2(3.4-7.3) 10 5.9(4.6-7.4) 5.3(3.9-6.9) 15 -10.1 (9.1-1 1.1) 11.3 (9.8-12.9) 5 MISO (5) 5.7(3.8-7.8) 7.6(5.4-10.3) 6.4(4.7-8.3) 7.5 MISO (5) 6.4(4.7-8.4) 11.1(9.0-13.5) 7.7(6.0-9.6) 5 1902 (2.5) 8.8(6.6-11.5) 6.9(4.8-9.4) 4.4(2.7-6.4) 7.5 1902 (2.5) 10.3(8.4-12.4) 9.6(7.9 -11.5) 9.6(8.3-10.9) Siemann (1981) ). This dose produces a peak plasma concentration in the mouse of 1.25 mM (Workman, 1980) . The maximum dose of MISO which is generally given in the clinic (i.e. 3 gm-2), however, only produces peak plasma levels of 0.5-0.75mM (Workman, 1980 There is, however, the additional factor that the elimination half-life of MISO is much longer in man than in the mouse, and this may, at least in part, compensate for lower peak levels. A number of studies have been, or are being, carried out to determine whether repeated administration of MISO to mice in order to maintain plasma levels at around 0.5mM (=l100pgmlP') can produce chemosensitization. Our own data indicate minimal chemosensitization to CCNU, CTX or MEL by a 7h regime of MISO administration, although a set of results showing greater sensitization has been reported by Brown and Hirst (1982 maintained between 2h and 8 h followed by a fall to 0.06mM at 16h (Workman et al., in preparation) . At a dose of 0.3mmol kg-1, the peak of 0.15 mM is achieved within 30 min, with a subsequent elimination half life of 2.1 h, giving a concentration of 0.025mM at 8h and undetectable levels by 24h (i.e. <2x 10-4mM). Our finding that significant enhancement of CCNU in the KHT tumour remains at 28h after 0.3 mmol kg-1 BENZO indicates that the effect is not dependent upon the presence of significant sensitizer plasma levels. On the other hand, the finding that, for both 0.3 and 2.5 mmolkg-' of BENZO, sensitization is similar for CCNU administration at 30 min and 8 h after BENZO would indicate that length of pre-exposure to a given plasma level of BENZO is not the critical factor and our data for the multiple injection regime with BENZO support this conclusion. We have recently shown that MISO, 1902 and BENZO all act as inhibitors of drug metabolism and that these same agents cause major changes in the pharmacokinetics of CCNU and its metabolites (Lee & Workman, 1983 and in preparation) . As far as MISO is concerned, the observed pharmacokinetic changes resulted in increased peak tumour concentrations of CCNU in the absence of any increase in peak concentrations in normal tissues, thus providing a likely basis for differential chemosensitization of the tumour enhance MEL (but not CCNU) in both tumour response (Table IV) and particularly in terms of LD50/30 (Table V) . In these circumstances it is not possible to determine the extent to which sensitization to MEL would be brought about by BENZO in the absence of vehicle effects.
At the present time, it appears to us that the combination of CCNU with BENZO offers the most promise of possible clinical benefit based on current experimental data for chemosensitization by nitroimidazoles.
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